A Trial of HBM9378 in Healthy Chinese Subjects

Summary

The objective is to evaluate the safety, tolerability and pharmacokinetic profile of a single subcutaneous injection of HBM9378 (SKB378) at different doses in healthy Chinese subjects.

Timeline

Start

2022-09-23

Primary completion

2023-10-24

Completion

2023-10-24

Publications

• Yang X, Xu M, Cao N, Zhao S, Wei Y, Lu J, Luo R, Ge J, Tao X, He W. Safety, Tolerability, and Pharmacokinetics of HBM9378 (SKB378/WIN378), a Fully Human IgG1 Monoclonal Antibody Against TSLP After Single Ascending Doses in Chinese Healthy Subjects. Drug Des Devel Ther. 2026 Mar 18;20:538649. doi: 10.2147/DDDT.S538649. eCollection 2026.

Drugs

Indications